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Abstract
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with no known 
cure. It is characterized by severe and persistent inflammation that damages multiple 
organs. To date, treatment and prevention of disease flares have relied on long-term use 
of anti-inflammatory drugs where side effects are of particular concern. There is a need 
for better understanding of the disease and for better approaches in SLE treatment and 
management. In this chapter, we delineate the roles of diet and microbes in the patho-
genesis of SLE.
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1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disorder with complex genetic and 
environmental etiology. It is characterized by severe and persistent inflammation that leads 
to tissue damage in multiple organs. The cause is unclear, and there is currently no cure. 
Current standard of care treatments for SLE are primarily nonselective immunosuppres-
sants, and not all patients respond to these regimens. Although current therapies can treat 
acute symptoms and reduce the risk of renal failure associated with SLE, side effects are a 
major cause of concern. Patients taking long-term immunosuppressants are prone to higher 
incidence of and more severe infections. There is an imperative need to develop new treat-
ment strategies against SLE, for which a better understanding of disease pathogenesis is 
required. In this chapter, we delineate the roles of diet and microbes in the pathogenesis 
of SLE.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. The hygiene hypothesis
Introduction. Environmental factors are known to impact lupus progression in both human 
and mouse. The role of environmental factors in the etiology of SLE is evidenced by the dra-
matic difference in disease incidence between West Africans and African-Americans, both 
derived from the same ethnic group but exposed to different environments. In addition, two 
remarkable cases of disease amelioration have been reported in SLE patients who had expe-
rienced multiple microbial infections. In lupus-prone mice, infections have also been dem-
onstrated to attenuate lupus-like disease. The mechanisms behind these observations are 
unclear, but improvement in hygiene and absence of certain microbes may have contributed 
to the higher incidence and faster progression of lupus disease. In this subsection, we will 
describe the hygiene hypothesis and its relationship with the pathogenesis of SLE.
SLE and the hygiene hypothesis. Proposed by Strachan [1], the hygiene hypothesis initially 
states that the increased incidence of allergies stems from “declining family size, improve-
ments in household amenities, and higher standards of personal cleanliness.” Since then, the 
scope of the hypothesis has expanded to cover several autoimmune diseases, including type 
1 diabetes (T1D), inflammatory bowel disease and multiple sclerosis. Many infectious agents 
have been described to be protective against autoimmunity [2, 3], whereas mouse models 
of these autoimmune diseases, such as NOD mice for T1D, are known to develop more pro-
gressive clinical signs in cleaner environments. In the case for SLE, it has been long recog-
nized that lupus-prone mice exhibit different disease courses in different animal facilities, 
suggesting an important role for environmental factors in the etiology of SLE. In addition, 
the incidence of SLE increased at least threefold in the second half of the twentieth century 
[4, 5], which is strongly correlated with the increase in hygiene and the decrease of infections, 
particularly those of the gastrointestinal tract [6]. We therefore have recently extended the 
hygiene hypothesis to SLE [7].
Protective infectious agents against SLE. The increase in hygiene could reduce infections that are 
either pathogenic or protective in SLE. Known triggers of lupus development include parvovirus 
B-19 [8], rubella virus [9], Epstein-Barr virus and cytomegalovirus (CMV) [7, 10–15]. Infectious 
agents that have been shown to be protective against SLE, on the other hand, include Helicobacter 
pylori, hepatitis B virus (HBV), Toxoplasma gondii, malaria parasites such as Plasmodium berghei 
and Plasmodium chabaudi and more recently described, helminths. In a large cohort of African-
Americans, H. pylori seronegativity was found to be associated with an increased risk and earlier 
onset of SLE [16, 17]. For HBV, only 2.5% of SLE patients were found to be positive for an HBV-
specific antibody, suggesting prior infection, whereas in the general population, >10% of peo-
ple are found positive for the same antibody [9, 18]. Besides human studies, it has been shown 
that the infection of T. gondii protects New Zealand Black (NZB)/New Zealand White (NZW) 
F1 hybrid (NZB/W F1) lupus-prone mice from developing SLE-like disease, with significantly 
decreased mortality, ameliorated lupus nephritis and reduced autoantibodies in the serum [19, 
20]. Infections with malaria-causing parasites also protected NZB/W F1 mice from developing 
clinical signs of murine lupus [21–24]. In another classical mouse model of SLE, MRL/Mp-Faslpr 
(MRL/lpr), helminthic infection and administration of helminth (worm)-derived molecules 
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have been recently shown to induce the regulatory functions of the immune system and attenu-
ate SLE-like disease such as glomerulonephritis and development of anti-nuclear antibodies 
[25–27]. Similar results have also been obtained in NZB/W F1 mice, although with a different 
worm-derived compound [28]. Interestingly, all these protective infectious agents are highly 
prevalent in Africa where the incidence of SLE is low. Due to vaccinations and the increase in 
hygiene such as higher quality of drinking water, people in North America and Europe are much 
less likely to be infected by these agents. Conversely, SLE is of high prevalence in Western devel-
oped countries, especially for people of African descent.
It is most remarkable, however, that multiple infections led to complete amelioration of lupus 
disease in two female patients previously diagnosed with the most active form of SLE [20]. 
Both women were of childbearing age, where pregnancy was found to be a trigger of lupus 
flares. In addition, their disease was refractory to all available treatments. Due to drug-induced 
immunosuppression, they experienced multiple infections over several months that included 
CMV and Staphylococcus aureus, which unfortunately induced sepsis. One patient also expe-
rienced infections of Pseudomonas aeruginosa and Pneumocystis carinii, whereas the other expe-
rienced multiple Escherichia coli urinary tract infections. Both were treated with antivirals 
such as ganciclovir and antibiotics such as vancomycin and trimethoprim-sulfamethoxazole. 
Remarkably, the course of lupus disease changed dramatically in both women with improved 
autoantibody titers. They were reported to be symptom free after 3–5 years of follow-ups, and 
one patient even had a normal pregnancy afterwards. While the authors of the reports sug-
gested that the infections had caused the amelioration of SLE symptoms, it is likely that the 
combination of infections and antiviral/antibacterial treatments had contributed to the change 
in disease course.
Mechanisms of protection. A couple of mechanisms could explain the protective effects of 
infectious agents against SLE. The first mechanism is competition. It is likely that the strong 
immune responses elicited by infectious agents can compete successfully for homeostatic sig-
nals (cytokines, growth factors, etc.) against the autoimmune response elicited by weaker 
autoantigens. The second mechanism is that regulatory cells stimulated by infectious agents 
can dampen autoimmune response. For example, type I interferons induced by some infec-
tious agents can induce the generation of IL-10-producing regulatory T cells (Treg or Tr1 cells) 
[29, 30] and limit the production of IL-17 from T cells [31], both of which are mechanisms to 
suppress autoimmunity. Besides regulatory T cells, anti-inflammatory dendritic cells (DCs) 
that produce IL-10 and transforming growth factor β (TGF-β) and drive T helper (Th)-2 
responses can be also induced by parasitic infections [3]. In addition, parasitic infections can 
promote IL-4 secretion from basophils and NKT cells, leading to a Th2-biased response to 
dampen Th1/Th17-induced autoimmunity [3]. Bacterial products, on the other hand, have 
been shown to directly induce IL-10-producing Treg cells [32]. Finally, toll-like receptors 
(TLR) appear to mediate the effects of protective infectious agents, which are TLR agonists, 
in preventing autoimmunity [6]. It is worth noting that these mechanistic studies were per-
formed with regard to T1D.
Specifically for SLE, several studies have tried to pinpoint the mechanisms by which protec-
tive infectious agents prevent lupus-like disease in mice. In response to T. gondii infection, 
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the levels of interferon (IFN)-γ and IL-10 decreased in NZB/W F1 mice, suggesting the 
repression of disease-facilitating Th1 and Th2 cytokines in the development of lupus-like 
nephritis [19]. In addition, alterations of the redox state in kidney and liver tissues may 
explain the protective effects of malarial infections against lupus nephritis [21]. A parasite-
derived compound tuftsin-phosphorylcholine, on the other hand, was able to enhance the 
expression of TGF-β and IL-10 as well as the expansion of Treg cells in NZB/W F1 mice, 
while at the same time inhibiting the expression of IFN-γ and IL-17 [28]. This suggests a 
shift of the balance between Th1/Th17 and Treg toward a Treg-biased phenotype that may 
in turn attenuate lupus-like disease. Moreover, infection of Schistosoma mansoni skewed the 
Th1:Th2 balance to a Th2 phenotype in MRL/lpr mice, which significantly changed the 
pathophysiology of glomerulonephritis from diffuse proliferative lupus nephritis (more 
severe) to membranous lupus nephritis (less severe) [25]. Furthermore, it has been found 
that a parasitic worm product ES-62 targets MyD88-dependent effector functions of B cells 
(promoting regulatory B cells and inhibiting plasmablast differentiation) to suppress auto-
antibody production and proteinuria in MRL/lpr mice [26, 27]. Altogether, these studies 
suggest that infectious agents can protect against the development of SLE by inducing the 
regulatory functions of immune cells.
3. Diet and SLE
Introduction. Environmental factors beyond microbial infections contribute to the pathogene-
sis and severity of disease progression in mouse models, as well as lupus patients. Nutritional 
components including vitamins, caloric excess or restriction, polyunsaturated fatty acid com-
position, excess sodium intake and exogenous hormone containing compounds all influence 
the clinical signs and immune system cellular responses. Nutritional compounds such as 
vitamin D, omega-3 fatty acids and conjugated linoleic acid appear to have beneficial effects 
on some parameters of lupus, while high levels of vitamin E, omega-6 fatty acids, a mod-
ern “western diet,” and high levels of circulating adipokines may exacerbate disease flares. 
Various commonly consumed phytoestrogens exert complex and differential effects, leading 
to regulation or exacerbation of SLE clinical signs. Modulating the immune system through 
dietary intervention to promote regulation of the immune response may form an adjunctive 
treatment to reduce signs of SLE both for maintenance as well as during disease flare-ups, 
while decreasing necessary dosages of systemic medications. In this section, we will discuss 
the role of diet in the pathogenesis of SLE.
Vitamin A. The three main isoforms of the ubiquitously expressed nuclear retinoic acid recep-
tor (RAR), α, β and γ, heterodimerize with the retinoic X receptor (RXR) isoforms. Retinoic 
acid binding to these heterodimers leads to promotion of retinoic acid-responsive genes 
through retinoic acid response elements (RAREs). The RXR receptors are also associated with 
multiple nuclear receptors, including peroxisome proliferator-activated receptor (PPAR) and 
vitamin D receptor (VDR). Retinoic acid and 1,25-dihydroxyvitamin D3 (D3), the active hor-
monal metabolite of vitamin D, have been described to potentially antagonize each other’s 
effects due to the similar binding patterns of RAR and VDR to RXR [33].
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Retinoic acid has many roles in the development of both innate and cell-mediated immu-
nity. Exposure of antigen presenting cells (APCs) to retinoic acid is critical for cell develop-
ment and establishment of normal cellular function, leading to an increase in co-stimulatory 
molecules and induction of the expression of CD11b, a critical adhesion marker, on murine 
splenocytes and human monocytes [34, 35]. Retinoic acid appears to have differential effects 
on the induction of immune responses. 9-cis retinoic acid decreases the production of IL-12 in 
macrophages. However, when combined with lipopolysaccharide (LPS), it augmented the 
production of nitric oxide, leading to promotion of the Th2 phenotype through regulation of 
cytokine production by APCs [34, 36, 37].
The development and differentiation of B and T cells are also influenced by the exposure to 
retinoic acid. Administration of retinoic acid contributes to increased CD19+ B cell numbers in 
the bone marrow and spleen, accelerated B cell maturation and increased expression of Pax-5, 
a transcription factor promoting early B cell development and expansion [33, 34]. Conversely, 
retinoic acid is reported by several groups to decrease mature B cell expansion by arresting 
B cells in the G0/G1 phase through increased expression of p27 (Kip1). This restricted prolifer-
ation may be necessary for the increased expression of CD38 leading to increased plasma cell 
numbers and production of IgG1 [34, 38–40]. Retinoic acid has also been reported to increase 
the proliferation of memory B cells when stimulated with the TLR9 ligand CpG and retinoic 
acid. Stimulation of B cells with both molecules led to a threefold increase in immunoglobulin 
secretion compared with cells stimulated with CpG alone [34].
Vitamin A deficiency has been associated with a decrease in CD4+ T cells, a decrease in the 
CD4+ to CD8+ ratio, decreased splenic germinal center formation, decreased total splenocytes, 
as well as splenic and thymus organ mass [41–43]. Deficiency of vitamin A also contributed to 
an increase in a Th1-driven immune response, with increased IFN-γ and IL-12 and a decrease 
in IL-5 and IL-10 production [41]. Administration of retinoic acid contributed to an increase 
in CD4:CD8 ratio and the promotion of a Th2-driven immune response with an increase in 
IL-5 production, while repressing IFN-γ and the Th1 response [37, 44]. The administration 
of a single dose of all-trans-retinoic acid in a murine model of lupus nephritis reduced the 
disease severity and production of Th1-associated cytokines IL-2 and IFN-γ [45]. Another 
study in the same NZB/W F1 model of lupus reported prolonged survival with decreases in 
total IgG, IgG2a and anti-dsDNA autoantibodies in the serum [46]. A major contribution to 
the development of lupus nephritis is the deposition of immunoglobulins and complement 
proteins in the glomeruli. Multiple groups have reported the protective effect of retinoic acid 
on the development of glomerular disease, leading to decreased proteinuria and glomerular 
damage, while maintaining similar levels of IgG and C3 deposition within the glomeruli [47]. 
Another study reported that retinoic acid inhibits Th1-phenotype-related genes T-bet and 
IRF-1, leading to a decrease in Th1-related cytokines and altering the Th1/Th2 balance, skew-
ing toward a type-2 response [48].
Retinoic acid administration to MRL/lpr mice contributes to the sustained function of natu-
ral T regulatory (Treg) cells and promotes the differentiation of inducible Treg cells in the 
peripheral tissues [36]. Enhanced differentiation of T cells to Treg cells was shown in the small 
intestine lamina propria, as well as upregulation of gut-homing receptors on Treg cells by the 
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binding of retinoic acid [36, 49]. There is discrepancy as to whether DCs or macrophages are 
the predominant cell type to induce Treg cell differentiation in the small intestinal lamina pro-
pria, while DCs are known to contribute to Th17 cell differentiation. It has been shown that 
human SLE patients exhibit a defective induction of Treg cells through TGF-β induction and 
retinoic acid expansion [37]. This impaired induction led to increased numbers of Treg cells 
with defective regulatory function abilities, causing the inducible Treg cells to be ineffective 
at controlling the autoimmune inflammatory response. The studies described above clearly 
show that cells of both the innate and adaptive immune system are regulated by vitamin A/
retinoic acid. Therefore, it is conceivable that vitamin A and its metabolites may have an effect 
on patients suffering from SLE.
Vitamin D. Vitamin D3 and its metabolites have been extensively studied and have shown 
to influence multiple functions in the body, including the abilities to affect bone density and 
strength, and to modulate both the innate and adaptive immune branches. In this chapter, 
we will focus on the evidence of vitamin D’s metabolites influence on the human immune 
system as it pertains to lupus. Vitamin D3 administration contributes to decreased pro-
inflammatory cytokine production by human monocytes, along with decrease dendritic cell 
maturation, while increasing IL-10, impairing the differentiation of T cells into Th1 cells [50]. 
D3 is also able to decrease the expression of MHC class II, CD40, CD80 and CD86 co-stimula-
tory molecules, decreasing the ability of DCs to present antigens to T and B cells. The ability 
of D3 to activate human monocytes and macrophages in vitro led to increased cathelicidin 
and IL-1 production [48].
D3 decreases the expression of IL-2, IFN-γ and T cell proliferation in vitro, as well as decreas-
ing CD8+ cytotoxic activity. It is important in the regulation of many genes, including IL-2 
and IFN-γ in T cells, through interaction with the vitamin D receptor-RXR heterodimer. 
Similar to retinoic acid, D3 inhibits the induction of the Th1-mediated immunity response in 
favor of the Th2 phenotype, through enhancing the production of IL-4 and decreasing IFN-
γ. The Th17 cell response is also mitigated by vitamin D through the inhibition of IL-6 and 
IL-23 production, leading to the promotion of the Treg cell phenotype through expansion of 
Foxp3 [51, 52].
It has not yet been determined if D3 acts directly on B cells to decrease B cell proliferation and 
induction of apoptosis. D3 is also associated with decreased plasma cell differentiation and a 
subsequent decrease in IgG secretion. In one study, the authors showed that D3 has the ability 
to upregulate p27 mRNA; however, p18 and p21 were not similarly upregulated in human 
purified B cells from patients with SLE. The p27 gene is associated with inhibition of the cell 
cycle, leading to decreased proliferation in activated human B cells, especially memory B cells 
[53].
Mouse models of SLE have shown decreased proteinuria and prolonged survival when sup-
plemented with D3. A commonly used therapy for human SLE patients is the administration 
of glucocorticoids to reduce inflammation and to broadly dampen the immune response [54]. 
Glucocorticoids have been shown to decrease the expression of the vitamin D receptor in 
multiple cell types. Conversely, D3 interferes with both glucocorticoid receptor and androgen 
receptor responsiveness through reduced receptor expression and impaired translocation to 
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the nucleus due to alterations in phosphorylation status [55]. When administered as a medica-
tion, D3 can lead to adverse effects, including hypercalcemia and bone resorption [48].
Though in vitro evidence strongly supports an immune-regulatory role of vitamin D and 
its metabolites in the adaptive immune system, there are conflicting reports regarding vita-
min D deficiency in SLE patients and the supportive role of vitamin D supplementation. The 
majority of studies describe decreased serum levels of D3 in patients with SLE compared to 
healthy patients, which correlated with increased disease activity. The current consensus is 
that vitamin D serum levels correlate inversely with disease activity, and vitamin D deficiency 
is associated with increased disease activity or severity [51, 56].
Vitamin E. Vitamin E is a potent antioxidant supporting the normal structure and function 
of cells by reducing damaging free radical reactive oxygen species (ROS). ROS have been 
implicated in tissue damage and an increase in pro-inflammatory cytokine production [57]. 
These factors support the development of autoimmune and degenerative disease severity. 
The preferentially absorbed form of vitamin E is α-tocopherol, which contributes to the nor-
mal function of the immune system in humans and mice. In one study, lowered antioxidant 
ability was found to precede the diagnosis of SLE, and oxidative damage was increased prior 
to diagnosis of SLE. This suggests that the decreased ability to control oxidative damage is a 
potential risk factor for development of SLE [58, 59].
Multiple studies in mouse models of SLE have shown that the dose of vitamin E had differ-
ential effects on the disease. Low-dose α-tocopherol increases the lifespan of NZB/W F1 mice 
while decreasing proteinuria, anti-dsDNA autoantibody IgG in the serum, IL-6 and IFN-γ 
production from splenocytes [60]. In the MRL/lpr mouse model, low-dose administration of 
vitamin E increases lifespan and IL-2 production. In contrast, high-dose vitamin E increases 
anti-DNA and cardiolipin IgM, as well as IL-4 and IL-10 from activated splenocytes. The 
authors conclude that the decreased survival in high-dose groups was due to the imbalance 
of Th1/Th2 cytokines, with Th2 cytokines leading to hyperactivation of the B cells in the MRL/
lpr model [61]. Vitamin E also increases the pro-inflammatory chemokine MIP-1α in MRL/
lpr mice, which activates granulocytes and promotes pro-inflammatory cytokine production 
[62]. A study comparing plasma antioxidant status between healthy patients and patients 
diagnosed with SLE showed that SLE patients have impaired plasma antioxidant status as 
well as a decreased antioxidant intake. The study was small and did not take into account 
dietary restrictions or food intolerance, limiting the ability to draw firm conclusions for a 
large set of SLE patients [58]. The above studies demonstrate that the dose of vitamin E is a 
critical determinant in amelioration or exacerbation of murine lupus. Response to vitamin E 
supplementation in human SLE patients needs to be thoroughly investigated to determine 
whether vitamin E supplementation is appropriate.
Omega 3:6 PUFA. Poly-unsaturated fatty acids (PUFAs) have been a popular topic of research 
in health due to their wide range of effects that can be exerted on the body. Omega-3 PUFAs 
generally have an anti-inflammatory role, lowering the severity of autoimmune disease and 
increasing survival in mouse models of SLE. In contrast, diets that are high in saturated fatty 
acids and omega-6 PUFAs lead to higher anti-dsDNA antibody, proteinuria and inflamma-
tory cytokines in mice [63, 64]. Mouse survival rates were not measured in these studies. 
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Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the main bioactive con-
stituents of omega-3 rich fish oil. SLE patients were shown to have decreased EPA in erythro-
cytes along with a decrease in the EPA to pro-inflammatory arachidonic acid ratio [65]. The 
evidence in human studies and clinical trials using omega-3 PUFAs in SLE patients is incon-
clusive at this time, with multiple studies showing no demonstrable effect on SLE disease 
activity index or other clinical scores and no effect of omega-3 fatty acids on glucocorticoid 
requirements when used as immunosuppressive medication.
In a mouse study using NZB/W F1 female mice, higher on concentrations of EPA and DHA 
led to increased lifespan, decreased glomerulonephritis, decreased anti-dsDNA antibodies, 
as well as a reduction in pro-inflammatory cytokines IL-1β, IL-6 and TNFα in splenocytes, 
relative to controls. The authors also demonstrated a reduction in nuclear factor-κB (NF-κB) 
and p65 nuclear translocation in mice fed higher concentrations of both EPA and DHA [66]. 
In studies using the MRL/lpr mouse model, fish oil altered pro-inflammatory chemokine pro-
duction, leading to a decrease in RANTES and MCP-1 from splenocytes [62]. In NZB/W F1 
mice, omega-6 PUFAs, conversely, led to an increase in IL-6 and TNFα production as well as 
prostaglandin E2 from macrophages, a decrease in TGF-β mRNA from splenocytes and lower 
anti-dsDNA IgG in the serum [67].
There is evidence that n-3 PUFAs remodel the lipid rafts in T cells, which can lead to a 
decrease in intracellular signaling through the T cell receptor, as well as binding to multiple 
PPARs. Omega-3 PUFAs bind to PPARα in T and B cells, whereas they bind to PPARγ in cells 
of myeloid lineage, leading to alterations in gene expression. The binding capacity to PPARs 
by n-3 and n-6 PUFAs is equal, suggesting that gene modulation between the different fami-
lies is unlikely, though the possibility exists for differences in cellular metabolism of n-3 and 
n-6 PUFAs to allow for distinct PPAR activation [65]. In certain instances, the evidence is 
contradictory between ex vivo and in vivo studies, and cytokine levels have been shown to be 
opposite in mouse models compared to human data [65]. While there is inconclusive evidence 
for the anti-inflammatory effects of n-3 PUFAs in human clinical trials, it is still recommended 
by some that rheumatic patients supplement their diet with long-chain n-3 PUFA and gamma 
linoleic acid [65].
Conjugated linoleic acid. Conjugated linoleic acid (CLA) has been described to provide health 
benefits in humans and makes up a group of isomers of linoleic acid. These fatty acids occur 
naturally in dairy and beef. CLA is considered to have anti-carcinogenic, anti-atherosclerotic 
and immune-enhancing abilities, with respect to lymphocytic cytotoxic function, macrophage 
activation and lymphocyte proliferation [68]. The isomer of CLA that demonstrates the stron-
gest anti-inflammatory effect is cis9, trans11-CLA, which accounts for up to 90% of the dietary 
CLAv [68].
Supplementation with CLA leads to a reduction in the loss of body mass during end-stage dis-
ease, along with an increase in survival after the onset of proteinuria in the NZB/W F1 mouse 
model [69, 70]. In a non-autoimmune mouse model and cell lines, CLA has a profound effect 
on macrophage functions. In BALB/c mice, CLA ameliorates LPS-induced body wasting and 
anorexia in vivo, decreases the production of nitric oxide from macrophages, and decreases 
the serum concentration of TNFα. Splenocytes from BALB/c mice fed the CLA supplement 
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also have a lower level of IL-4 production and an increase in IL-2 production after stimulation 
with concanavalin A [71]. CLA also decreases macrophage adhesion as well as downregu-
lating multiple atherogenic genes associated with leukocyte adhesion, while inducing the 
antagonist IL-1Rα in human umbilical cord vein endothelial cells and the RAW macrophage 
cell line [72].
CLA is able to exert immune-modulatory effects on dendritic cells and subsequent differentia-
tion of T cells in mice. DCs produce multiple cytokines after activation and express MHC II on 
the cell surface to facilitate interactions with T cells and B cells. Exposure of DCs to CLA led 
to a decrease in IL-12 and an increase in IL-10 production, along with decreased migration 
to the lymph nodes [73]. CLA decreased the expression of MHC II and costimulatory mol-
ecules CD80 and CD86 on the surface of DCs, reducing the DC’s ability to trigger T cell and 
B cells responses [74]. When exposed to LPS stimulation in mice fed a CLA rich diet, serum 
levels of IFN-γ, IL-1β and IL-12p40 were decreased [75]. CLA decreases the ability of DCs to 
induce the T helper cell differentiation into Th1 and Th17 cells, as well as directly suppress-
ing the production of IL-17 and IL-2 by Th17 cells [74]. The mechanism for CLA influencing 
the DC response after activation with LPS was shown to be through suppression of both 
NF-κB and IRF3 downstream of TLR4 [75]. The immune-modulatory effects have been well 
described in mouse models, though data for the effects of CLA in human SLE patients are 
lacking at this time.
Western diet and obesity. Considerable attention has recently been given to the attributes 
of dietary components that make up the typical diet in the developed countries, termed the 
“western diet.” These factors include high-fat, high-protein, high-sugar and high-salt, as well 
as consumption of a large portion of processed foods. These nutritional components pro-
mote obesity, metabolic syndrome and cardiovascular disease. In addition, a recent study 
has shown the role of the “western diet” in promotion of autoimmune disorders [76]. White 
adipose tissue is now considered to be a major endocrine organ, secreting more than 50 adi-
pokines including leptin, adiponectin, resistin and visfatin, along with pro-inflammatory 
cytokines IL-6 and TNFα [76, 77]. Excess white adipose tissue drives a low-level steady state 
inflammation, which may contribute to various autoimmune and inflammatory-mediated 
diseases.
The connection between obesity and the development of SLE is complex, and contradic-
tory information exists among studies. There was no correlation found in Danish women 
between obesity and the incidence of SLE after 11 years [77, 78]. This cohort study had mul-
tiple limitations, such as reliance on survey questionnaires regarding pre-pregnancy weights 
and diagnoses, potential socio-economic bias with women of lower socioeconomic status 
being underrepresented in the Danish National Birth Cohort, and the confounding factor of 
pregnancy and childbirth during the study, which do not allow for conclusions to be drawn 
regarding the link between obesity and SLE [78]. Childhood obesity rates correlated posi-
tively with incidence of childhood-onset SLE. The adipokine leptin has been extensively stud-
ied and exerts multiple effects on the body [79]. Leptin promotes satiety and stimulation of 
energy expenditure, by acting on the hypothalamic nuclei, as well as contributing to fertility, 
bone metabolism and having a profound effect on the immune system. Lack of leptin, due to 
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starvation, testosterone or glucocorticoids, can lead to immunosuppression, while upregula-
tion of leptin by inflammatory cytokines or female sex hormones, 17β-estradiol and proges-
terone, can lead to inflammation [79]. Leptin can induce the production of IL-6, IL-12 and 
TNFα pro-inflammatory cytokines from macrophages, while stimulating the proliferation 
of naïve T cells and promoting a Th1 immune response. Leptin inhibits the production of 
Th2 cytokines IL-4 and IL-10, along with inhibiting T regulatory cell proliferation [80]. The 
formation of a pro-inflammatory state through increased leptin levels may contribute to auto-
immune disease development.
Leptin is commonly elevated in obese patients as well as SLE patients, which contributes 
to the survival of autoreactive T cells, and a decrease in the functional T regulatory cells, 
while promoting the proliferation of Th17 cells in a mouse model of SLE [81, 82]. Circulating 
serum leptin levels as well as leptin secretion have been shown to be higher in females com-
pared to males, both in obese and non-obese subjects. The sex difference in leptin secretion 
may be a contributing factor in the development of female-predominant SLE. Leptin defi-
ciency in murine models of SLE has led to decreased anti-dsDNA and a decrease in severity 
of SLE symptoms [83, 84]. The increased level of circulating leptin may also contribute to the 
exacerbation of cardiovascular damage in some SLE patients [85, 86]. Adiponectin deficiency 
was correlated with an increase in SLE disease severity [87, 88]; however, another study found 
increased levels of adiponectin in the serum and urine of human patient with lupus nephritis 
[89]. Little information is available regarding other adipokines and their involvement with 
SLE development.
Obesity is correlated with a predisposition to metabolic syndrome, with increased rates of 
hypertension, dyslipidemia and atherosclerosis, as well as subsequent cardiovascular disease. 
Atherosclerosis and cardiovascular disease are highly prevalent in patients with SLE, and a 
significant number of patient deaths occur due to cardiovascular disease, while obesity has 
been linked to worsening renal disease and cardiovascular disease in patients suffering from 
SLE [77]. High levels of inflammatory markers and elevated leptin concentrations found in 
SLE patients, and mice have been correlated with decreased cognitive function, increased 
renal damage and increased cardiovascular risks [90, 91].
Diets high in salt (sodium chloride) are found in multiple regions throughout the world, mainly 
in developed countries where processed foods and “fast food” are prevalent. Excess sodium 
intake has been attributed to cardiovascular disease and hypertension, as well as stroke, and is 
now being studied in the development of autoimmune diseases [76]. T cells in a hyperosmotic 
environment show an increase in p38/MAPK as well as transcription factor NFAT5, leading to 
an altered cellular response [92]. Sodium can be stored in the human body in various tissues, 
leading to hyper-osmotic environments in multiple tissues during high-dietary salt intake. 
Human and murine T cells were investigated under high salt conditions in vivo that led to 
the promotion of Th17 differentiation in vitro [93]. High salt intake has been associated with 
a decrease in glucocorticoid therapy response in a study of 260 Chinese SLE patients treated 
with prednisone and followed for 12 weeks [94]. Further studies need to be performed to deter-
mine the mechanism for hyperosmotic conditions to promote the highly pro-inflammatory 
Th17 cell differentiation.
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Phytoestrogens. Endogenously produced estrogen contributes significantly to the develop-
ment of SLE and disease progression. Estrogen is able to suppress IL-2, enhancing the effect 
of autoantigens. 17β-estradiol implants led to an increase in IFN-γ, nitric oxide and a range 
of cytokines and chemokines in murine splenocytes [95]. The estrogen receptors on cells com-
prise two subtypes, α and β. Estrogen receptor-α (ERα) mRNA was increased in the periph-
eral blood mononuclear cells of SLE patients, while estrogen receptor-β (ERβ) was decreased. 
ERα was shown to be predominantly pro-inflammatory in a mouse model of SLE, leading 
to increased proteinuria and decreased survival time when activated, while ERβ showed an 
immunosuppressive phenotype by decreased autoantibody anti-DNA IgG2 [96, 97].
Phytoestrogens are plant compounds that exert an estrogenic or an anti-estrogenic effect on 
the human body through interaction with both estrogen receptor α and β, with a preferential 
binding to ERβ [97]. Phytoestrogens can also block the binding of more potent estrogenic 
compounds to the ER and regulate target genes. Many types of phytoestrogens are found nat-
urally, with soy-based phytoestrogens, isoflavones, present in many of the foods consumed 
in industrialized societies. Due to the ubiquity of phytoestrogens in normal diets, controlled 
human trials are lacking with regard to the specific effects of phytoestrogens on SLE dis-
ease development. Data from mouse experiments involving supplementation of isoflavones 
to MRL/lpr mice show a decrease in IFN-γ from splenocytes with a decrease in anti-dsDNA 
and cardiolipin levels in the serum, along with a reduction in proteinuria and renal dam-
age through preferential binding of the ERβ [98]. Exclusion of dietary isoflavones through 
diets using casein as the protein source rather than soy led to amelioration of glomerulone-
phritis [99]. Alfalfa sprout extract supplementation to MRL/lpr mice produced similar results 
with decreased renal damage and increased survival, while decreasing IFN-γ and IL-4 pro-
duction by splenocytes. Alfalfa sprout extract was also able to reduce TNFα, IL-6 and IL-1β 
pro-inflammatory cytokines in a mouse model of endotoxic shock [100]. Coumestrol, one 
phytoestrogen in alfalfa, was able to decrease anti-dsDNA IgG and decrease proteinuria in 
the NZB/W F1 mouse model [101]. However, these findings have not been observed in human 
SLE patients, where ingestion of alfalfa tablets, which contain all phytoestrogen components 
of the alfalfa plant, exacerbated disease severity [102].
Multiple phytoestrogens have been shown to upregulate VDR expression in various human cell 
lines. Genistein and glycitein upregulated VDR transcription and translation in colon cancer cells, 
while resveratrol and genistein also increased VDR expression in breast cancer cells [103, 104]. 
Along with receptor expression, genistein decreased CYP24, an enzyme responsible for metabo-
lism of the vitamin D metabolite D3 [105]. Phytoestrogens are abundant in many diets throughout 
the world and are able to contribute to the modulation of the immune system through interaction 
with estrogen receptors, potentially ameliorating or exacerbating patients’ clinical signs.
4. The role of gut microbiota
Introduction. The mammalian gut harbors trillions of microorganisms known as the micro-
biota. Increasing evidence in recent years suggests that host microbiota and immune system 
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interact to maintain tissue homeostasis in healthy individuals. The importance of microbiota 
on the host is highlighted by altered immune responses in the absence of commensal bacte-
ria. Higher susceptibility to infectious pathogens and in some cases, attenuated symptoms 
in autoimmune disorders, has been observed in mice raised under germ-free conditions. 
Indeed, perturbation of the host microbiota, especially that in the gut, has been shown to be 
associated with many autoimmune diseases, including SLE. Changes of gut microbiota in 
nephritic lupus mice versus healthy controls have recently been described, where a decrease 
of Lactobacillaceae and an increase of Lachnospiraceae were observed in lupus-prone mice. A 
cross-sectional study has also shown that a lower Firmicutes to Bacteroidetes ratio was present 
in the fecal microbiota of SLE patients with inactive disease, which is consistent with observa-
tions in other autoimmune diseases. In addition, oral antibiotics are known to trigger lupus 
flares, again suggesting a role for commensal bacteria in SLE. In this section, we will describe 
the existing data and a proposed role of gut microbiota in the pathogenesis of SLE.
Gut microbiota and SLE. Evidence is rapidly growing that mutualistic bacteria contribute 
to the development of a healthy functioning immune system, as well as the development of 
aberrant immune responses. The past 10 years have seen a rapid growth in the understanding 
of how the commensal microbiota is able to contribute to health and disease with the explora-
tion of 16S rRNA sequencing along with the use of gnotobiotic animals. These newer methods 
of DNA sequencing have allowed researchers to investigate the effects of specific species or 
strains of organisms and how they interact with the immune system. Gnotobiotic animals are 
born into a sterile environment and develop under sterile conditions so that a specific group 
of bacteria, viruses, eukaryotes or parasites can be introduced to the animal, and the resulting 
effects can be studied without the interference of other organisms [106]. Intestinal microbial 
dysbiosis can lead to immune system effects at distant sites of the body [49, 107–112]. The sys-
temic immune system is influenced by microbiota in the intestines, suggesting that microbiota 
at other sites of the body can also have a systemic effect on the host’s immune system.
The host’s genetic make-up is the primary factor in determining the composition of one’s 
adult microbiota. Other contributing factors include mother’s health in utero, the method 
of delivery during birth, if one is either breast fed or fed formula, the use of antibiotics 
during early childhood and types of foods consumed prior to, and during, weaning. The 
adult microbiota is not a static entity, however, and can be modified through many different 
environmental factors, and the composition will also change with age. Many of the previ-
ously discussed contributions to SLE are associated with alterations in the microbiota. Obese 
patients have an increased Firmicutes to Bacterioidetes ratio, with members of Firmicutes lead-
ing to increased energy harvest from dietary nutrients [113]. The “western diet” is associ-
ated with alterations in the gut microbiota as well. Children from a rural village in the West 
African country of Burkina Faso had increased microbial richness and greater Prevotella with 
decreased Bacteroides levels compared to European children. The microbiota of the Burkina 
Faso children also produced more short chain fatty acids than the intestinal microbiota of 
the European children [114]. These findings of agrarian societies with increased Prevotella 
and decreased Bacteroides have been supported in studies comparing rural South Americans 
and people from Bangladesh to people living in industrialized regions [115]. The source of 
dietary fat can impact microbiota composition as well, as mice fed diets with a fat source 
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from either milk-fat, lard, safflower oil or a low-fat diet, all resulted in distinct phylogenetic 
profiles [116, 117].
Murine studies on how the microbiota affects the immune system have emerged recently. 
At the level of the intestinal lamina propria, bacteria compete with host defenses and establish 
homeostasis. T cells are kept in check between pro-inflammatory Th1, Th2 and Th17 cells as 
well as innate lymphoid cells, and the anti-inflammatory T regulatory cells [118–120]. Specific 
bacterial groups can elicit distinct immune responses, as evidenced by mice colonized with 
segmented filamentous bacteria developed elevated levels of Th17 cells in the lamina propria 
[121, 122]. Colonization of previously germ-free mice with clostridial strains from cluster IV 
and XIVa resulted in an expansion of the T regulatory cell population in the lamina propria 
and systemically [123]. Polysaccharide A derived from Bacteroides fragilis is able to induce 
IL-10 production in the lamina propria through binding to TLR2 on T regulatory cells, inhib-
iting the expansion of the local Th17 cell population [124]. Only a single study, reported in 
1999, to date has explored the development of SLE in a germ-free mouse strain. That study 
used MRL/lpr mice and showed no difference in disease progression between conventionally 
raised mice and germ-free mice [125]. Due to the Fas mutation and the underlying cause of 
lupus disease in this strain of mice, the MRL/lpr strain may not be the best strain to under-
stand the impact of gut microbiome in a germ-free setting on lupus. Few murine studies 
investigating the microbiota’s role in SLE have been published to date. Regardless, gut micro-
biome in MRL/lpr mice has recently been shown to impact lupus. In the MRL/lpr mouse 
model of SLE, young female mice had lower numbers of Lactobacilli species and increased 
numbers of Lachnospiraceae density in the murine feces. The administration of retinoic acid 
restored the Lactobacilli density and correlated with reduced clinical signs and a reverse of 
multiple lupus-associated microbial functions. The increased density of Lachnospiraceae was 
also overrepresented in female lupus-prone mice along with butyrate producing Clostridiaceae 
species. There is potential that use of Lactobacilli containing probiotics and vitamin A may 
benefit lupus patients [49, 107].
There have been few human trials to determine the impact on intestinal microbiota specifi-
cally on SLE development. In 20 human SLE patients in remission compared to healthy con-
trols, a decreased Firmicutes to Bacterioidetes ratio was found in fecal samples. This change in 
fecal microbiota is associated with an increase in oxidative phosphorylation and glycan utili-
zation by the host microbiota [126, 127]. In contrast to the murine studies, Lachnospiraceae and 
Clostridia were associated with healthy patients, rather than lupus patients [126]. The intesti-
nal microbiota is a complex conglomeration that can contribute to modulation of the local and 
systemic immune system. Current and future work will begin to target specific groups and 
mechanisms of microbial contribution to systemic autoimmune disease pathogenesis.
5. Bacterial metabolites and mechanisms of action
Introduction. Bacterial metabolites produced by the gut microbiota may have profound effects 
on immune function. Recently, several groups have found that short-chain fatty acids (SCFAs) 
produced by gut microbiota, especially butyrate produced by Clostridia, can promote the 
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 differentiation of regulatory T (Treg) cells in the colon, spleen and lymph nodes and suppress 
inflammation [128–131]. Treg deficiency leads to autoimmunity, while re-introduction of Treg 
cells can rescue animals from the disease. In human SLE, a pathogenic role of dysfunctional 
Treg cells has been suggested. In particular, the imbalance between Treg and Th17 cells and 
a bias toward IL 17-producing cells (both Th17 cells and double-negative T cells can pro-
duce IL-17 in SLE) are widely recognized for SLE. In the gut, the number and diversity of 
butyrate-producing bacteria are subject to factors related to age, disease and to diet. Butyrate 
and SCFAs are inhibitors of histone deacetylases (HDACs). HDAC inhibition can result in 
altering gene expression by making the chromatin more accessible to transcription factors by 
acetylating histone proteins at specific lysine residues and may also lead to post-translational 
modification of several transcription factors that reside both cytosolic and nuclear. Below, 
we have outlined the influence of SCFAs (predominately butyrate) on HDAC activity on the 
epithelia in the gut microbiota as it is likely to play an important role in regulation of the gut 
microbiota and lupus.
Role of epigenetics in immunity. Although genome-wide association studies have identi-
fied many genes that may play a role in the initiation or progression of SLE [132–134], these 
studies do not account for risk attributed to heritable factors [135] and have failed to iden-
tify a unifying switch. Epigenetics is the process in which alterations in gene expression 
and phenotype occur which are heritable but do not alter the DNA sequence [136]. There 
is increasing evidence that epigenetics plays a key role in SLE pathogenesis and epigeneti-
cally targeted therapies may be efficacious [137, 138]. In regard to epigenetics, interactions 
between DNA and core histone proteins are important in regulating the accessibility of 
transcription factors to bind promoter regions and thus regulate gene expression [139]. 
Histone acetyltransferases (HATs) and HDACs can alter the charge and subsequent bind-
ing affinity of core histone proteins to the chromatin through removal or addition of acetyl 
groups on lysine residues, respectively [140–142]. Recent investigations have revealed that 
HATs and HDACs are also capable of modifying lysine residues on numerous non-histone 
nuclear and cytosolic proteins [141, 143], which has driven some researchers to alterna-
tively refer to the enzymes as lysine (K) acetyltransferases (KATs) and lysine deacetylases 
(KDACs).
HDAC enzymes. There are 18 mammalian HDACs, which remove acetyl groups from lysine 
residues in histones and other proteins to control multiple cellular functions including tran-
scription, cell cycle kinetics, cell signaling and cellular transport processes [144]. HDACs are 
classified based on structure, homology to yeast HDACs and function into classes I–IV [145, 
146]. Class I HDACs (HDAC-1, -2, -3 and -8) are nuclear exclusive enzymes found in a wide 
range of tissues and cells lines where they are known for histone modification and repression 
of transcription [147, 148]. Class II HDACs are further subdivided into class IIa (HDAC-4, -5, 
-7 and -9) and class IIb (HDAC-6 and -10) based on domain organization [149] and exhibit 
selective tissue expression, nucleocytoplasmic shuttling and function through recruitment of 
distinct cofactors [148]. Class III comprises the sirtuins, which act through a distinct NAD+-
dependent mechanism and are not considered “classical” HDACs [147]. HDAC11 is the sole 
member of class IV as phylogenetic analysis revealed very low similarity to HDACs in the 
other classes [150].
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In addition to their initial relevance in cancer biology [151], HDAC enzymes are now increas-
ingly being investigated as regulators of inflammation and immunity [147]. As reviewed by 
Shakespear et al., HDACs are documented to play a role in myeloid development, toll-like 
receptor (TLR) and interferon (IFN) signaling in innate immune cells, antigen presentation 
and development and function of B and T lymphocytes [147]. Subsequently, pharmacologic 
inhibition of HDACs has been evaluated as a possible treatment modality in a wide spectrum 
of diseases, including inflammatory and autoimmune diseases [152].
SCFAs. Intestinal bacteria provide the hosts with nutrients and confer resistance to infec-
tion. The delicate balance between pro- and anti-inflammatory mechanisms, essential for 
gut immune homeostasis, is affected by the composition of the commensal microbial com-
munity and has been reviewed by others [153]. Recent studies have shown that metabolism 
and immunology are intertwined and the field of immunometabolism has emerged which 
examines how gut metabolites influence immune cell function [154]. In the gut, carbohydrates 
resistant to breakdown in the stomach and small intestine are subject to colonic fermenta-
tion to result in the production of SCFAs, containing1–6 carbon atoms. Anaerobic bacteria 
generate the major SCFAs and include acetate, propionate and butyrate. The SCFA butyrate 
is produced by fermentation of dietary fiber by the intestinal microbiota and is the primary 
energy source of colonocytes [155]. Recently, Imhann and coworkers showed that patients 
with inflammatory bowel disease (IBD) had a decrease in the genus Roseburia. Furthermore, 
they noted that Roseburia spp. is acetate-to-butyrate converters suggesting that a lack of butyr-
ate may contribute to IBD [156]. Furthermore, a reduction on butyrate producing Roseburia 
ssp. has been associated with chronic kidney disease progression [157]. On the other hand, 
butyrate has seen shown to aggravate dextran sulfate sodium induce colitis in an animal 
model [158]. In regard to HDAC inhibition, butyric acid has been reported to specifically 
inhibit the class I HDACs (1, 2, 3 and 8) [159].
T cells in gut immunity. Balanced mucosal immunity in the gut is critical for host homeostasis 
and defense. Naïve CD4+ T cells when activated differentiate into T helper cell [Th1, Th2, Th17 
or follicular helper (Tfh)] depending on cytokine exposure and B cell or antigen presenting 
cell influence. One specific subset of T cells (Treg cells) acts to suppress effect T cell func-
tion. The majority of Treg cells develop in the thymus (nTregs) and are selected for by 
strong or intermediate T cell receptor (TCR) signals while escaping negative selection [160]. 
Additionally, Treg cells can also be induced under certain circumstances from naïve T cells in 
the periphery (iTregs). This can happen systemically and has been shown to occur at interface 
with the environment in both whole animal and in in vitro assays [161]. Treg differentiation is 
strongly influenced by the presence of the anti-inflammatory cytokine transforming growth 
factor β (TGF-β). Furthermore, expression of the transcription factor Foxp3 is essential for 
Treg development and function and is regulated by genomic regulatory elements termed con-
served noncoding DNA sequences (CNS). While CNS1 is unnecessary for nTreg differentia-
tion, it has been reported to be crucial for iTreg generation in gut-associated lymphoid tissues 
(GALT) [162]. CNS2 is required for Foxp3 expression in the progeny of dividing Treg cells. 
CNS3 controls de novo Foxp3 expression and nTreg differentiation [163]. Studies have shown 
that Treg cells expressing transcription factor Foxp3 have a key role in limiting inflammatory 
responses in the intestine [164, 165].
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Treg-Th17 balance. Th17 is a subset of T helper cells and serves to maintain the mucosal bar-
rier and contribute to pathogen clearance at mucosal surfaces. However, they have also been 
implicated in autoimmune and inflammatory disorders as the loss of Th17 cells at mucosal 
surfaces has been shown to allow chronic inflammation and microbial translocation. In the 
gut, there exists a balance of Treg-Th17 cells as the signals that cause Th17s to differentiate 
actually inhibit Treg differentiation [166]. Since both Treg and Th17 cells are both pertinent to 
gut homeostasis and immune regulation, the balance of these T cells is critical for homeostasis 
[167]. Treg cells prevent systemic and tissue-specific autoimmunity and inflammatory lesions 
at mucosal interfaces [165]. Mice deficient in iTregs spontaneously developed pronounced 
Th2-type pathologies at mucosal sites including in the gastrointestinal tract and lungs and 
shows hallmarks of allergic inflammation and asthma [168]. Studies have shown that in the 
gut, iTreg cells are the prominent phenotype and are rapidly induced following naïve T cell 
activation which is dependent on Notch2-singling and may be somewhat independent of 
TGF-β [165]. This suggests that whereas nTreg cells generated in the thymus appear suffi-
cient for control of systemic and tissue-specific autoimmunity, extrathymic differentiation of 
iTregs affects the commensal microbiota composition and serves a distinct, essential function 
in maintaining the inflammatory response at mucosal interfaces. Furthermore, when the ani-
mals were given the SCFA (butyrate), Treg cell differentiation in the gut increased and this 
was dependent on CNS1 expression [129]. In addition to butyrate, de novo iTreg generation 
in the periphery was potentiated by propionate, another SCFA of microbial origin capable 
of HDAC inhibition, but not acetate, which lacks this HDAC-inhibitory activity, suggesting 
that bacterial metabolites mediate communication between the commensal microbiota and 
the immune system. Other studies have also reported that a butyrate-mediated increase in 
the Treg cell subset in vivo was due to increased extrathymic generation of Treg cells and not 
due to their increased nTreg cells [169]. In addition to butyrate inducing a Treg phenotype, 
butyrate has also been shown to increases macrophage phagocytosis and killing of bacteria. 
When Treg cells were cultured with stimulated macrophages exposed to IL-4 and butyrate, 
less inflammatory cytokines were produced compared to macrophages treated with IL-4 indi-
cating that microbial-derived butyrate decreases inflammatory mediator production in the 
gut [170]. In other studies using the antibiotic vancomycin, which targets Gram-positive bac-
teria, the level of iTregs was reduced. This could be due to the decrease in Roseburia spp. that 
is the butyrate-producing, Gram-positive anaerobic bacteria that inhabit the human colon. 
However, when specific pathogen-free mice were treated with a combination of vancomycin 
and SCFAs, the reduction in iTregs was completely restored suggesting that SCFAs play a role 
in iTreg homeostasis [128].
HDAC and Treg-Th17 balance in lupus. HDAC inhibition has been shown to decrease disease 
in lupus-prone MRL/lpr and NZB/W F1 mice [171–174]. Mechanisms by which HDAC inhi-
bition decreases SLE disease have previously been reviewed by Reilly and others [142, 175]. 
HDAC inhibition may act in several ways including correction the hypoacetylation states of 
histones H3 and H4 [176], increased CD4+CD25+Foxp3+ Treg cells [172, 174], reduced Th1- 
and Th17-inducing cytokines (IL-12 and IL-23) as well as Th1-attracting chemokines [142], 
and inhibition of germline and post-switch immunoglobulin transcripts in splenic B cells 
[177]. More importantly in SLE, decreased renal disease (glomerulonephritis and protein-
uria) has been consistently reported in studies investigating the use of HDAC inhibitors to 
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treat lupus in various mouse models [171–174]. Pan and selective HDAC inhibitors are being 
evaluated in the clinic for inflammatory diseases with some mixed results and adverse effects 
such as fatigue, nausea, vomiting, diarrhea, thrombocytopenia, neutropenia and cardiac 
irregularities [178]. Investigations of specific functions for each HDAC isoform in knockout 
mice have revealed that elimination of class I and class IIa HDACs result in embryonic lethal 
phenotypes or fatal cardiac, vascular, musculoskeletal or neural crest defects, and specific 
HDAC isoform activity is required for normal cells development [178, 179]. The observed 
butyrate-mediated increase in the Treg cell subsets in vivo due to increased extrathymic gen-
eration of Treg cells and not due to their increased thymic output would support a role of 
HDACi in gut homeostasis [169]. In studies involving lupus patients, while Treg or Th17 cells 
alone were not correlated with SLE development, the ratio of Treg to Th17 cells in active 
SLE patients was significantly lower than that in inactive SLE patients and healthy controls. 
Moreover, corticosteroid treatment increased the ratio of Treg to Th17 cells in active SLE 
patients. Indeed, the Treg/Th17 cell ratio is inversely correlated with the severity of active 
SLE, indicating that in active SLE, there appears to exist an imbalance between Treg and 
Th17 cells [180]. Inducible Tregs cells are dependent on the expression of the transcription 
factor Foxp3 which may be transiently expressed allowing for plasticity of the Tregs/Th17 
phenotype [181]. Interestingly, when Foxp3 is acetylated, the transcription factor becomes 
more stable and has greater propensity to bind DNA yielding a more stable and effective Treg 
population [182]. In addition to the regulation of Treg differentiation, butyrate has also been 
shown to increase the tri-methylation of lysine 27 on histone 3 (H3K27me3) in the promoter 
of nuclear factor-κB1 (NF-κB1) in colon tissue resulting in repression of inflammation [183]. 
In our lupus mouse studies, we found a marked depletion of lactobacilli in our lupus animals 
and increases in Lachnospiraceae compared to age-matched health controls. Interestingly, we 
also found that Lachnospiraceae, butyrate-producing genera, was more abundant in the gut 
of lupus-prone mice at specific time points during lupus progression [49]. Whether this was 
causative or in response to disease pathogenesis is an active area of investigation in our labo-
ratory. Nonetheless, our results and others demonstrate the dynamics of gut microbiota as 
that bacterial production of SCFAs and butyrate may play a role in the initiation and progres-
sion of inflammation and autoimmunity.
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